Use of lipid lowering therapy in patients at high and very high CV risk in Europe
Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study
Presented at the ESC congress 2021 by: Prof. Kausik Ray, MD - London, UK
Introduction and methods
The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.
SANTORINI is a multinational, prospective, observational study that is twice the size of the previous DAVINCI study. A total of 9606 patients at high or very high CV risk requiring lipid lowering therapy (LLT) were recruited from March 2020 to February 2021 from 14 European countries across primary and secondary care settings. Cleaned data from 4308 patients were available through to February 2021 and presented at the ESC Congress 2021.
- 69.3% Of patients were classified as very high risk and 30.6% of patients as high risk. Risk classification was in 51.3% of cases based on the ESC/EAS guidelines, in 33.5% on clinical experience and in 10.4% on national guidelines.
- At baseline, 18.6% of patients at high or very high CV risk were not receiving any LLT.
- 54.1% of patients received LLT as monotherapy at baseline (51.1% statins, 1.4% ezetimibe, 1.2% a PCSK9 inhibitor and 0.5% other oral LTT).
- Combination LLT was used in 27.3% of patients at baseline (17.1% statin + ezetimibe, 4.1% PCSK9 inhibitor + oral LLT, and 6.1% other oral combination therapy).
These interim results of the SANTORINI study, show that at baseline, Patients at high or very high CV risk were not receiving any LLT, 54.1% received LLT as monotherapy, and 27.3% of patients received combination LLT.
More data from the SANTORINI study will be presented later this year.
-Our reporting is based on the information provided at the ESC Congress-
Share this page with your colleagues and friends: